Covance Co-Locates Facility for Increased Patient Exposure
LabCorp® announced that Covance Drug Development has relocated its clinical research unit in Dallas, TX, to a new, fit-for-purpose clinical research facility.
LabCorp® announced that Covance Drug Development has relocated its clinical research unit in Dallas, TX, to a new, fit-for-purpose clinical research facility. This unit opened earlier this month and has expanded from 72 to 100 medical beds. In addition, a LabCorp patient service center will be co-located in the CRU, at which patients will have an opportunity to learn more about volunteering and participating in early stage clinical trials.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
